 |
|
COMMENTS AND OPINIONS
Adverse Events in Patients Receiving Cholinesterase Inhibitors Due to Dissimilar Follow-up Periods—Reply
Sudeep S. Gill, MD, MSc;
Chaim M. Bell, MD, PhD;
Paula A. Rochon, MD, MPH
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We thank Dr Chan for his interest in our study,1 and we agree that cholinesterase inhibitors may provide clinical benefits for some patients with Alzheimer disease. The goal of our study was to better characterize underrecognized adverse effects of these medications. Dr Chan highlights the shorter mean follow-up time among cholinesterase inhibitor users compared with nonusers in our study, which was detailed in Table 3 of our article.1 These findings are similar to those in randomized trials, in which it has been consistently demonstrated that there is a higher dropout rate for patients assigned to treatment with cholinesterase inhibitors than for patients assigned to placebo.2 Clinical experience supports this observation, which appears to be due primarily to adverse drug effects such as nausea and diarrhea. Thus, the patients who used cholinesterase inhibitors in . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Syncope and Its Consequences in Patients With Dementia Receiving Cholinesterase Inhibitors: A Population-Based Cohort Study
Sudeep S. Gill, Geoffrey M. Anderson, Hadas D. Fischer, Chaim M. Bell, Ping Li, Sharon-Lise T. Normand, and Paula A. Rochon
Arch Intern Med. 2009;169(9):867-873.
ABSTRACT
| FULL TEXT
RELATED LETTER
Adverse Events in Patients Receiving Cholinesterase Inhibitors Due to Dissimilar Follow-up Periods
Mark Chan
Arch Intern Med. 2009;169(18):1724.
EXTRACT
| FULL TEXT
|
